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Substrates of the N-end rule pathway include proteins with
destabilizing N-terminal residues. Three of them, Asp, Glu, and
(oxidized) Cys, function through their conjugation to Arg, one
of destabilizingN-terminal residues that are recognized directly
by the pathway’s ubiquitin ligases. The conjugation of Arg is
mediated by arginyltransferase, encoded by ATE1. Through its
regulated degradation of specific proteins, the arginylation
branch of the N-end rule pathway mediates, in particular, the
cardiovascular development, the fidelity of chromosome segre-
gation, and the control of signaling bynitric oxide.We show that
mouse ATE1 specifies at least six mRNA isoforms, which are
produced through alternative splicing, encode enzymatically
active arginyltransferases, and are expressed at varying levels in
mouse tissues.We also show that theATE1 promoter is bidirec-
tional,mediating the expression of bothATE1 and an oppositely
oriented, previously uncharacterized gene. In addition, we iden-
tified GRP78 (glucose-regulated protein 78) and protein-disul-
fide isomerase as putative physiological substrates of arginyl-
transferase. Purified isoforms of arginyltransferase that contain
the alternative first exonsdifferentially arginylate theseproteins
in extract from ATE1/ embryos, suggesting that specific iso-
forms may have distinct functions. Although the N-end rule
pathway is apparently confined to the cytosol and the nucleus,
and although GRP78 and protein-disulfide isomerase are
located largely in the endoplasmic reticulum, recent evidence
suggests that these proteins are also present in the cytosol and
other compartments in vivo, where theymay becomeN-end rule
substrates.
A protein substrate of the ubiquitin (Ub)2-proteasome sys-
tem, which controls the levels of many intracellular proteins, is
conjugated to Ub through the action of ubiquitin-activating
enzyme (E1), ubiquitin-conjugating enzyme (E2), and ubiq-
uitin-protein ligase (E3) (1–7). The term “Ub ligase” denotes
either an E2-E3 holoenzyme or its E3 component. The selectiv-
ity of ubiquitylation ismediated largely by E3, which recognizes
a degradation signal (degron) of a substrate (1, 3, 8–12). The E3
Ub ligases are an exceptionally large family, withmore than 500
distinct E3s in a mammal (5, 12–14). A ubiquitylated protein
bears a covalently linked poly-Ub chain and is targeted for pro-
cessive degradation by the 26 S proteasome (15–19). Ub has
other functions as well, including nonproteolytic ones (20, 21).
An essential determinant of one class of degrons, called
N-degrons, is a destabilizing N-terminal residue of a substrate.
The set of destabilizing residues in a given cell type yields a rule,
called the N-end rule, which relates the in vivo half-life of a
protein to the identity of its N-terminal residue (1, 22–26). In
eukaryotes, the N-degron consists of three determinants: a
destabilizing N-terminal residue of a protein substrate, its
internal Lys residue(s) (the site of formation of a poly-Ub
chain), and a conformationally flexible region(s) in the vicinity
of these determinants that is required for the substrate’s ubiq-
uitylation and/or degradation (8, 23, 27–29).
The N-end rule has a hierarchic structure (Fig. 1A). In
eukaryotes, N-terminal Asn and Gln are tertiary destabilizing
residues (denoted as Ndt) in that they function through their
enzymatic deamidation (30, 31), to yield the secondary destabi-
lizing N-terminal residues Asp and Glu (denoted as Nds). The
destabilizing activity of the N-terminal Asp and Glu requires
their conjugation, by ATE1-encoded isoforms of Arg-tRNA-
protein transferase (arginyltransferase or R-transferase), to
Arg, one of the primary destabilizing residues (denoted as Ndp)
(26, 32–37). The latter N-terminal residues are recognized by
E3 Ub ligases of the N-end rule pathway, called N-recognins
(23–25, 38, 39) (Fig. 1A). The N-end rule pathway of the yeast
Saccharomyces cerevisiae is mediated by a single N-recognin,
UBR1 (40, 41), while at least fourN-recognins, includingUBR1,
mediate this pathway in mammals (24, 25, 38, 39, 42). In mam-
mals and other eukaryotes that produce nitric oxide (NO), the
set of arginylated residues contains not only Asp and Glu but
also N-terminal Cys (C) (43), which is arginylated after its oxi-
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dation (36). The in vivo oxidation of N-terminal Cys requires
NO, as well as oxygen (O2) or its derivatives (Fig. 1A) (26, 37).
Althoughprokaryotes lackUb conjugation andUb itself, they
contain (Ub-independent) N-end rule pathways (44–47). The
sets of destabilizing residues in prokaryoticN-end rules contain
secondary destabilizing (Nds) residues as well. Their identities
(Arg and Lys in Escherichia coli; Arg, Lys, Asp, and Glu in some
other prokaryotes) are either overlappingwith, or distinct from,
the eukaryotic Nds residues (47). The activity of Nds residues in
prokaryotes requires their conjugation to Leu (an Ndp residue)
by Leu-tRNA-protein transferases (L-transferases), in contrast
to the conjugation of Arg (an Ndp residue in eukaryotes) to
N-terminal Asp, Glu, or (oxidized) Cys (Fig. 1A) (44, 47). Pro-
karyotic L-transferases are of two distinct types, differing in
both amino acid sequence and substrate specificity. Remark-
ably, L-transferases of one class, encoded by bpt genes, are
sequelogs of ATE1-encoded eukaryotic R-transferases, despite
the fact that Bpt (prokaryotic) aminoacyltransferases conjugate
Leu, rather than Arg, to the N termini of cognate substrates
(47). (In this terminology, “sequelog” and “spalog” denote,
respectively, a sequence that is similar, to a specified extent, to
another sequence and a three-dimensional structure that is
similar, to a specified extent, to another three-dimensional
structure (48). Sequelog and spalog are mnemonically helpful,
single word terms whose rigor-conferring advantage is their
evolutionary neutrality. The sequelog terminology conveys the
fact of sequence similarity (sequelogy) without evolutionary or
functional connotations, in contrast to interpretation-laden
terms such as homolog, ortholog,
and paralog. The latter terms are
compatible with the sequelog/spa-
log terminology and can be em-
ployed to convey understanding
about functions and common
descent, if this information is actu-
ally available (48).)
The functions of the N-end rule
pathway include the regulation of
import of short peptides (through
the degradation, modulated by pep-
tides, of the import’s repressor) (41,
49), the fidelity of chromosome seg-
regation (through the degradation
of a conditionally produced cohesin
fragment) (50), the regulation of
apoptosis (through the degrada-
tion of a caspase-processed inhib-
itor of apoptosis) (51, 52), the reg-
ulation of meiosis (24), the leaf
senescence in plants (53), as well
as neurogenesis and cardiovascu-
lar development in mammals (26,
36, 37, 39). Mutations in human
UBR1, one of several functionally
overlapping N-recognins (Fig. 1A)
(25, 39), are the cause of Johanson-
Blizzard syndrome, which in-
cludes mental retardation, physi-
cal malformations, and severe pancreatitis (54). The
abnormalities of UBR1/ mice (38) include pancreatic
insufficiency (54), a less severe version of the defect in
human Johanson-Blizzard syndrome (UBR1/) patients.
The cardiovascular and (probably) other functions of the
N-end rule pathway involve the arginylation-mediated degra-
dation of RGS4, RGS5, and RGS16. These “GTPase-activating”
proteins function by inhibiting the signaling by specific G pro-
teins, and are themselves down-regulated through the NO/O2-
dependent degradation by the N-end rule pathway. The N-ter-
minal Cys residues of RGS4, RGS5, and RGS16 are oxidized in
vivo at rates controlled by NO and oxygen, followed by the
arginylation of oxidized Cys and processive proteolysis by the
rest of the N-end rule pathway (Fig. 1A) (26, 35, 37). The argi-
nylation branch of this pathway is also required for degradation
of the in vivo-produced fragment of the mammalian RAD21/
SCC1 subunit of cohesin.3 This fragment, a part of circuits that
control mitosis and meiosis, is produced through a cleavage by
separase (55) and bears N-terminal Glu (an Nds residue) in
mammals (56) but N-terminal Arg (an Ndp residue) in S. cer-
evisiae (50). Given the tripartite structure of N-degrons, it is
possible that some physiological substrates of R-transferase
would be found to lack a complete N-degron, i.e. that their
arginylation would not be followed by their degradation.
All eukaryotes examined, from fungi to plants and animals,
3 J. Zhou, J. Sheng, R.-G. Hu, Y. T. Kwon, and A. Varshavsky, unpublished data.
FIGURE 1. ThemammalianN-end rule pathway. A, the pathway. N-terminal residues are indicated by single-
letter abbreviations for aminoacids. The yellowovalsdenote the rest of aprotein substrate.MetAPs,methionine
aminopeptidases. C* denotes oxidized N-terminal Cys, either Cys-sulfinic acid (CysO2(H)) or Cys-sulfonic acid
(CysO3(H)), produced in reactionsmediated by nitric oxide (NO) and oxygen (O2) or its derivatives, with subse-
quent arginylation of oxidized Cys by the ATE1-encoded isoforms of Arg-tRNA-protein transferase (R-transfer-
ase) (26). (NO is produced from Arg by NO synthases.) The type 1 and type 2 primary destabilizing N-terminal
residues are recognized by multiple E3 ubiquitin ligases (N-recognins) of the N-end rule pathway, including
UBR1 and UBR2. Through their other substrate-binding sites, these E3s also recognize internal (non-N-termi-
nal) degrons in other substrates of the N-end rule pathway, denoted by a larger oval. The marks of omission
after “calpains” refer to the expectation that physiologically relevant N-degrons can also be produced by
intracellular proteases additional to those cited. B, MetAPs removeMet from theN terminus of a polypeptide if
the residue at position 2 belongs to the set of residues shown (23, 87).
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contain both R-transferases and the N-end rule pathway. The
former are sequelogous (similar in sequence) (48) throughout
most of their 60-kDa spans, even between highly divergent
eukaryotes such as fungi and mammals (34). A single gene,
ATE1, encodes R-transferase in both S. cerevisiae (32) and the
mouse or human genomes (34, 36), whereas plants such asAra-
bidopsis thaliana contain two genes, ATE1 and ATE2, which
encode sequelogous R-transferases (53). Our previous studies
described the cloning of yeast and mouse ATE1, and also the
finding that mammalian (but not S. cerevisiae) R-transferase
occurs as two isoforms, produced through alternative splicing
of ATE1 pre-mRNA (32, 34). The two mouse R-transferases
were shown to be of identical sizes (516 residues), differing by a
stretch of 43 residues, encoded by two alternative, adjacent and
sequelogous 129-bp exons (34).
In this work, we continued the analysis ofmouseATE1, iden-
tifying six splicing-derived isoforms of ATE1 mRNA and also
discovering that the ATE1 transcriptional promoter is bidirec-
tional, driving the expression of both ATE1 and an oppositely
oriented, previously uncharacterized gene. In addition, we
identified GRP78 (BiP) and protein-disulfide isomerase (PDI),
two proteins located primarily in the endoplasmic reticulum
(ER), as putative physiological substrates of R-transferases. Sev-
eral lines of evidence (57–60) suggest that bothGRP78 and PDI
can be present in non-ER compartments as well, including the
cytosol and the nucleus, where these proteins may be targeted
by the N-end rule pathway.
A recent paper by Rai and Kashina (61) described two new
splicing-derived mouse ATE1 isoforms, in addition to the two
previously known ones (34). The authors claimed that the four
R-transferases could arginylate unmodified N-terminal Cys
and also that the two new R-transferases were inactive with
N-terminal Asp or Glu (61). We show that both of these con-
clusions are incorrect: the activity of known R-transferases
toward unmodified N-terminal Cys is negligible, and the two
isoforms of R-transferase stated to be inactive with the N-ter-
minal Asp and Glu (61) are actually active with these residues.
EXPERIMENTAL PROCEDURES
Yeast Strains, Plasmids, and -Galactosidase Assay—Syn-
thetic yeast media (62) contained 0.67% yeast nitrogen base
without amino acids (Difco) and either 2% glucose (SD
medium) or 2% galactose (SG medium). Synthetic media lack-
ing appropriate nutrients were used to select for (andmaintain)
specific plasmids. Cells were also grown in rich medium (YPD)
(62). The S. cerevisiae strains were YPH500 (MAT ura3-52
lys-801 ade2-101 his3-200 trp1-63 his3-200 leu2-1),
SGY3 (MAT ura3-52 lys2-801 ade2-101 trp1-63 his3-200
leu2-1 ate1-2::LEU2), and JD55 (MAT ura3-52 lys2-801
trp1-63 his3-200 leu2-3,112 ubr1-1::HIS3) (63). AVY34B,
aubr1 ate1 doublemutant, was constructed by replacing the
entire ATE1 open reading frame in JD55 (ubr1) by the antibi-
otic resistance gene G418, using homologous recombination
with G418 flanked on either side by 40 bp of ATE1-specific
sequences (62). Mutants were selected on SD lacking His and
containing G418. G418-resistant isolates were checked by PCR
(for the absence of ATE1), by functional assays, and by N-ter-
minal sequencing of X--galactosidase (X-gal) reporters (26,
34) (see below). pUB23-X, a set of high copy plasmids express-
ing Ub-X-gal reporter proteins (with X the varying residue)
from the galactose-inducible PGAL1 promoter, was described
previously (22). The cDNAs of mouse ATE1 isoforms or
mutants thereof were PCR-amplified and cloned into the low
copy (CEN) vector p414GalS (64), which was modified by the
addition of BamHI and XhoI restriction sites. The resulting
plasmids, p414GalS-ATE1-X, expressed specific ATE1 iso-
forms (Fig. 1D) and their derivatives from the PGALS promoter
(64) in S. cerevisiae. Yeast transformation was performed using
the lithium acetate method (62). The activity of gal was meas-
ured as described previously (28, 30, 34, 40), using nitrophenyl-
-D-galactopyranoside as a gal substrate and S. cerevisiae
strains transformed with both pUB23-Asp and specific
p414GalS-ATE1-X plasmids.
N-terminal Sequencing of X-Gal Reporters—S. cerevisiae
AVY34B (ubr1 ate1) was cotransformed with pUB23-Asp
(expressing Ub-X-gal) and either the p414GalS vector or
p414GalS-ATE1–1A7A (expressing ATE11A7A). Cultures of
both transformants were grown in SG to A600 of 0.8, fol-
lowed by the addition of galactose to 2%, to induce the
expression of both Asp-gal (Ub-Asp-gal) and mouse
ATE11A7A (see Fig. 2B for ATE1 notations). Growth was
allowed to continue untilA600 of1.2, followed by collection
and disruption of cells (26, 34). -Galactosidase was purified
by affinity chromatography on p-aminophenyl-1-thio--D-ga-
lactopyranoside-agarose beads (Mobitec, Go¨ttingen,Germany)
and further fractionated by SDS-10% PAGE. A Coomassie-
stained band of gal was electroblotted onto Sequiblot mem-
brane (Bio-Rad), followed by N-terminal sequencing (at
CaltechMicrochemistry Facility) of30 pmol of gal, using at
least five cycles of Edman degradation and the Applied Biosys-
tems 476A sequencer.
RT-PCR—Total RNA frommouse embryonic fibroblast (EF)
cell lines, embryos, or tissues of adult mice was isolated using
mini RNA isolation kit II (Zymo Research, Orange, CA),
according to the manufacturer’s instructions. The Oligotex kit
(Qiagen, Valencia, CA) was then employed to isolate mRNA
from total RNA. Using 5 g of total RNA or 50 ng of total
mRNA as templates, the first strand cDNAs were retrotrans-
cribed using the Superscript kit and oligo(dT) primer (Invitro-
gen). Retrotranscription samples were used to carry out PCR,
using standard procedures (62) and the following primers (“f”
and “cr” denote “forward” and “complementary reverse” prim-
ers, respectively): 1Af, 5-CAGAACATGGCCTCGGTGGT-
GGA-3; 1Bf, 5-CAGAACATGGCTTCTTGGAGCGCG-3;
7Acr, 5-GGAATCTTGTAAACTGGCTCACGGTT-3; 7Bcr,
5-GGAATCTTGTAAACTCAGACTTTT-3 (these primers
were used to clone ATE1 cDNA isoforms); BamHIATE1Af,
5-CGCGGATCCCAGGTTGTTGTACAGAACATGGCC-
TCGGTGGTGGA-3; BamHIATE1Bf, 5-CGCGGATCCC-
AGGTTGTTGTACAGAACATGGCTTCTTGGAGCGCG-
3; XhoIATEC1, 5-CTAGCTCGAGTCAGTGTCTGAACAGC-
AGCATC-3;mATEexon6cf, 5-GCATCGCACAAGTTAGAGT-
TTACAAGATTCCTTTGCAGCTCACC-3; mATEexon6cr,
5-CTCTAACTTGTGCGATGCATTTTCTGGT-3 (these
primers were used to construct deletion derivatives
ATE11A(7AB) and ATE11B(7AB)).
Arginyltransferase
OCTOBER 27, 2006•VOLUME 281•NUMBER 43 JOURNAL OF BIOLOGICAL CHEMISTRY 32561
 at CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y on Novem
ber 10, 2006 
w
w
w
.jbc.org
D
ow
nloaded from
 
Arginylation Assay—The in vitro arginylation assay with
mouse embryo extracts was performed as described previously
(36), with slight modifications. Briefly, the C-terminally His6-
tagged mouse ATE1 isoforms ATE11B7A, ATE11A7A, and
ATE11B7B (Fig. 2B) were expressed in Sf9 insect cells (Invitro-
gen) using the baculovirus system andwere purified using nick-
el-nitrilotriacetic acid beads (Qiagen), as described in detail for
the ATE11B7A (ATE1-1) isoform (26). Either wild-type 12.5-
day-old (E12.5) (ATE1/) embryos (containing endogenous
R-transferases) or ATE1/ E12.5 embryos (26, 36) were lysed
using motorized pestle (Kimble/Kontes, Vineland, NJ) in a
hypotonic buffer (5 mM KCl, 5 mM MgCl2, 1 mM EDTA, 5 mM
-mercaptoethanol, 20 mM HEPES, pH 7.5). The samples were
centrifuged at 105,000 g in the TL100 ultracentrifuge (Beck-
man Instruments, Fullerton, CA), and the supernatants, termed
S105, which contained 2 mg/ml of total protein, were col-
lected. Specific components of [3H]Arg-based arginylation
assays, including embryo extracts, are mentioned under
“Results and Discussion” and are described in detail elsewhere
(36). The incubation time was 1 h at 37 °C. For one-dimen-
sional electrophoretic analyses,
the reaction was stopped by add-
ing 20% CCl3COOH to 5% (fi-
nal concentration). Precipitates
were collected by centrifugation,
washed with 90% ethanol, dried,
and resuspended in SDS-PAGE
sample buffer, followed by
SDS-10% PAGE, as described (36).
For two-dimensional electro-
phoretic analyses, the reactions
were stopped (in addition to
removing unincorporated [3H]Arg)
by aquickbuffer exchange tobufferA
(5 mM Tris-HCl, pH 7.8), using Cen-
tricons (Millipore, Billerica,MA), fol-
lowed by lyophilization.
Two-dimensional Electrophoresis
and Mass Spectrometric Identifica-
tion of Proteins—Two-dimensional
electrophoretic analyses of our sam-
ples were carried out by Kendrick
Laboratories, Inc. (Madison, WI).
Isoelectric focusing was performed
using 13-cm strips (pH range 4–10)
(Amersham Biosciences). Second-
dimension fractionation was by
SDS-10% PAGE, using 20-cm-long
gels. The latter were stained with
Coomassie Blue, treated with
Enhancer (PerkinElmer Life Sci-
ences), and vacuum-dried, followed
by fluorography with Kodak
BioMax film for 2 weeks at
80 °C. Image matching of fluoro-
graphs to Coomassie-stained gels
was carried out manually. The rele-
vant spotswere excised from the gel,
followed by processing for in-gel digestion with trypsin and
mass spectrometry (MS/MS), which was performed at the Pro-
tein Analysis Facility of the Columbia University (New York).
Mammalian Cell Culture—NIH-3T3 cells were grown at
37 °C and 5% CO2 in Dulbecco’s modified Eagle’s medium
(Mediatech, Herndon, VA) containing 10% heat-inactivated
fetal bovine serum and supplemented with penicillin/strep-
tomycin/glutamine (Invitrogen). The medium was changed
every 2–3 days, and cells were subcultured before reaching
90% confluency.
Northern Hybridization—Multiple tissue Northern blots
containing 2 g of mouse poly(A) RNA per lane (Clontech)
were probed with a 701-bp DNA fragment that was produced
by PCR amplification from EST-AW414102 (GenBankTM),
using the primers 5-ACTTTACAGTTGCTAGATAAGC-3
and 5-GTCCAATGACGAAGCGACAC-3. The amplified
fragment, corresponding to genomicDNAbetween1603 and
903 relative to the start of ATE1 exon 1B, was 32P-labeled
using the RediprimeII random prime labeling system (Amer-
sham Biosciences) according to the manufacturer’s protocol.
FIGURE 2. Arginyltransferase isoforms and bidirectionality of the ATE1 promoter. A, the exons, including
alternative exons, of the mouse ATE1 gene, with deduced lengths of the corresponding peptide segments
indicatedon top.B,mouseR-transferase isoforms encodedby theATE1mRNAs (see themain text).C, sequence
comparisons of translated vertebrate ATE1 exons 1A among themselves and to the set of longer but also
sequelogous (48) alternative exons 1B. Most of recurrent amino acid identities are highlighted by color. Mus
musc., mouse; Rattus norv., rat; Homo sap., human; Gallus gall., chicken. D, bidirectional promoter upstream of
the ATE1 exon 1B. The indicated sequence elements at the 5-end of the mouse ATE1 gene include the (alter-
native) exon 1A (87 bp; question mark denotes the currently unknown location of promoter element(s) for
transcripts that include exon 1A); the (alternative) exon 1B (108 bp); an 200-bp, high CpG DNA segment
immediately upstreamof exon 1B that functions as a bidirectional promoter (see themain text); and exon 2 (63
bp) of themultiexon ATE1. The stated sizes (in bp) of exons 1A and 1B refer to the protein-coding lengths; their
actual lengths, which include their 5-untranslated regions remain to be determined. Green arrows indicate
transcriptional units, including a previously uncharacterized gene, oriented head-to-head relative to ATE1
and transcribed, at least in part, from the bidirectional promoter6 (see the main text).
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Hybridization was carried out for 12 h at 68 °C in ExpressHyb
solution (Clontech). The blot was thenwashed twice for 15min
at room temperature in 2 SSC, 0.1% SDS, once for 15 min at
room temperature in 0.1 SSC, 0.1% SDS, and once for 30 min
at 50 °C in 0.1 SSC, 0.1% SDS, followed by autoradiography.
Luciferase Gene Fusions and Analysis of the ATE1 Promoter—
pGL3-empty was constructed by removing the PSV40 promoter
from the pGL3 promoter vector (Promega, Madison, WI), by
digesting it with KpnI and HindIII, blunt-ending the resulting
larger fragment with T4 DNA polymerase, and circularizing it
using T4 DNA ligase. The pGL3-derived plasmids pCB30,
pCB40, pCB41, pCB42, pCB43, pCB44, pCB107, and pCB108
were constructed as follows. Various 5-untranslated regions of
the mouse ATE1 gene were amplified by PCR using the primer
sets indicated below. Upon amplification, a 5-KpnI site and a
3-HindIII site were incorporated into the PCR-produced frag-
ments. These (modified) genomicDNA fragments were used to
replace the entire PSV40 promoter in pGL3 promoter vector, by
digestion with KpnI and HindIII and ligation with T4 DNA
ligase. The pGL3-derived plasmids pCB59F and pCB59R were
constructed by PCR amplification of mouse genomic DNA
(regions 1 and 2; see “Results and Discussion”), from 223 to 32
bp upstream of the ATE1 exon 1B, using primers CB34 and
CB33 andproducing aHindIII site at both the 5- and 3-ends of
the resulting fragment. It was then digested with HindIII and
ligated to KpnI/HindIII-cut pGL3 promoter vector. This step
yielded amixture of nicked plasmids containing the above frag-
ment (in either orientation) directly upstream of the firefly
luciferase gene. The sample was then treated with T4 DNA
polymerase and ligated using T4 DNA ligase. The above Hin-
dIII-flanked PCR fragment was also subcloned into pCB30, fol-
lowed by digestion with HindIII, producing pCB60F and
pCB60R. To minimize variability caused by differences in
transfection efficiency, we cotransfected pGL3-derived plas-
mids, expressing the firefly luciferase gene, along with the pRL-
SV40 plasmid (Promega), expressing the Renilla luciferase
gene. The firefly and Renilla luciferases have dissimilar sub-
strate requirements,making it possible, with the dual-luciferase
reporter assay system (Promega), to measure their lumines-
cence separately for each enzyme.
Primers used for construction of luciferase fusions are as
follows: CB02, 5-GATCAAGCTTCCGTTCCTCCTCTGT-
GAG-3; CB28, 5-GATCGGTACCGCTAGCACTTTACA-
GTTGCTAGATAAGC-3; CB29, 5-GATCAAGCTTGCC-
ACGCCTCTCAGCGC-3; CB32, 5-GATCGGTACCGGG-
ATTCCAGCACAGTG-3; CB33, 5-GATCAAGCTTGTC-
CTACGCAGCCGCCG-3; CB34: 5-GATCAAGCTTCTC-
ACAGAGGAGGAACGGA-3; CB112, 5-GATCGGTACC-
GCTAGCGCGCTGAGAGGCGTGGC-3; CB113, 5-GAT-
CGGTACCGCTAGCGTCCTACGCAGCCGCCG-3; CB114,
5-GATCAAGCTTGCGCTGAGAGGCGTGGC-3. Primer
sets for PCR of various ATE1 5-regions (plasmid/forward/
reverse primer) are as follows: pCB30/CB28/CB29; pCB40/
CB32/CB29; pCB41/CB32/CB02; pCB42/CB32/CB33; pCB43/
CB28/CB33; pCB44/CB28/CB33; pCB59/CB34/CB33;
pCB60/CB34/CB33; pCB107/CB112/CB33; and pCB108/
CB113/CB114.
Transient Transfection and Dual Luciferase Assay—About
20 h before transfection, NIH-3T3 cells were seeded at 1.5 
105 cells per 3.5-cm well. Cells at 60–70% confluency were
transfected with 1 g of a pGL3-derived plasmid and 0.4 g of
pRL-SV40 vector (Promega) per well, using 10 g of Lipo-
fectamine and 15 g of Plus reagent (Invitrogen), according to
the manufacturer’s protocol. 48 h post-transfection, cells were
lysed by incubation in 0.5 ml of Passive Lysis Buffer (Promega)
per 3.5-cmwell on an orbital shaker at room temperature for 15
min. The extracts were clarified by centrifugation at 16,000 g
for 10min at 4 °C. For luciferase assays, 10–40l of extract was
mixed with 0.2 ml of LARII reagent (Promega), and the firefly
luciferase levels were immediately measured over 10-s inter-
vals, using a Wallac luminometer 1250. The levels of Renilla
luciferase (the second, calibrating reporter) were then meas-
ured over 10-s intervals by adding 0.2 ml of “Stop & Glo” rea-
gent (Promega). Light units were recorded as a ratio of firefly-
to-Renilla luciferase levels, and values obtainedwere compared
with those conferred by the pGL3 promoter vector (containing
the PSV40 promoter) under the same conditions.
RESULTS ANDDISCUSSION
ATE1 Exon Terminology—To accommodate, terminology-
wise, the presence of an alternative ATE1 exon 5 to the
previously described exon 1 (34), and to make the notations
for R-transferase (ATE1) isoforms explicit in regard to the
two pairs of alternative (and sequelogous) exons, the six
ATE1 mRNAs and corresponding proteins (see below) are
denoted as follows: ATE11A7A, ATE11A7B, ATE11B7A,
ATE11B7B, ATE11A7AB, and ATE11B7AB (Fig. 2, A and B). The
names of the first four ATE1 isoforms above correspond,
respectively, to the following earlier names (34, 36, 61):
ATE1–3, ATE1–4, ATE1–1, and ATE1–2.
Splicing-derived Isoforms of Mouse ATE1—Work by this lab-
oratory has shown that prokaryotes, in addition to containing
L-transferases (encoded by aat genes) (44, 45) that are nonse-
quelogous to theATE1-encoded eukaryotic R-transferases, also
contain a distinct family of bpt-encoded L-transferases that are
sequelogs (48) of eukaryotic ATE1 R-transferases (see Intro-
duction) (47). One of the most highly conserved sequences in
ATE1 R-transferases is CGYC. It is present near N termini of
these enzymes (Fig. 2C) and is important for their activity.4
Although all examined R-transferases (they are confined, so far
without exception, to eukaryotes) contain CGYC, a more gen-
eral motif, CXYX (with restrictions on the identities of variable
residues), is conserved in the eukaryotic/prokaryotic ATE1/Bpt
superfamily of aminoacyltransferases. A search in data bases for
mammalian sequelogs of CGYC-containing sequences identi-
fied an expressed sequence tag (EST) that was later found to
correspond to the alternative first exon of ATE1, termed 1A
(Fig. 2, A–C).
To determine whether in vivo transcripts containing other
parts of ATE1-coding sequence contained exon 1A as well, RT-
PCR was carried out using primers derived from both exon 1A
and the sequences encoding the C termini of the alternative
exons 7A or 7B of the previously characterized (34) isoforms
4 R.-G. Hu, F. Du, and A. Varshavsky, unpublished data.
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ATE11B7A and ATE11B7B. The results, using mouse brain
mRNA (Fig. 3 and supplemental Fig. S1), showed that exon 1A,
similarly to its previously characterized sequelog exon 1B, was
present in transcripts of the expected length containing exon
7A or exon 7B, two previously characterized (34) alternative
(and sequelogous) exons of equal sizes. We concluded that the
in vivo synthesis and processing of ATE1 pre-mRNA produces
at least four distinct mRNAs, ATE11A7A, ATE11A7B; ATE11B7A,
and ATE11B7B. Among the 10 sequenced ATE1 cDNA isolates
produced by RT-PCR (using exon 1A-specific forward primer
and exon 12-specific complementary reverse primer), 9 isolates
corresponded to ATE11A7AmRNA and only one corresponded
to ATE11A7B mRNA, suggesting lower levels of the latter spe-
cies in brain mRNA (see below).
RT-PCR was also employed to characterize the (approxi-
mate) relative levels of mouse ATE1mRNA isoforms. The pre-
viously identified (34) ATE11B7A mRNA was found to be a
major species in every examined tissue except for spleen and
skeletalmuscle, whereasATE11B7B, the other previously known
isoform (34), was expressed at comparable or slightly lower
levels in the brain, liver, and testis, was a minor species in the
spleen, muscle, and heart, and was virtually absent from the
kidney, in contrast to ATE11B7A (Fig. 3). The third isoform,
ATE11A7A, was the major species in the muscle and was rela-
tively high in the testis, kidney, heart, and spleen but was pres-
ent at lower levels in the brain, and at still lower levels in the
liver (Fig. 3). ATE11A7B, the fourth isoform, was expressed at
readily detectable levels only in the kidney, testis, and muscle
(Fig. 3), in agreement with low frequency of full-length
ATE11A7B isolates produced by RT-PCR from brain mRNA.
Two additional species, of slightly larger than expected sizes,
were amplified by RT-PCR from themuscle- and testis-derived
samples specific for ATE11A7B, and from the testis-derived
samples specific for ATE11B7B (Figs. 3 and supplemental Fig.
S1). DNA sequencing revealed that these species corresponded,
respectively, to ATE11A7AB and ATE11B7AB mRNAs, encoding
slightly longer ATE1 isoforms that differed by the first alterna-
tive exons, 1A and 1B, and contained both of the alternative
internal exons, 7A and 7B (Fig. 2, A and B). The removal of the
(shorter) intron between the exons 7A and 7B, instead of a
(longer) intron that in addition contained either 7A or 7B (Fig.
2A), lengthened but did not frameshift the ATE1 open reading
frame. The levels of ATE11A7AB in the muscle and testis were
approximately equal to those of the (shorter) ATE11A7B iso-
form, whereas ATE11B7AB was significantly less abundant than
ATE11B7B in the testis, the only tissue where ATE11B7AB was
detectable (Fig. 3). The finding of ATE11A7AB and ATE11B7AB
increases the total number of known ATE1mRNA isoforms to
six (Fig. 2B). Whether all or only some of the mouse ATE1
isoforms (identified as mRNAs and characterized as recombi-
nant proteins expressed in E. coli or S. cerevisiae) exist as natu-
rally translated proteins in the mouse remains to be deter-
mined, because the current polyclonal antibody tomouseATE1
was raised against one isoform, the full-length ATE11B7A (26),
and would be expected to recognize all six isoforms (Fig. 2B).
The larger isoforms, ATE11A7AB and ATE11B7AB, would be
expected to differ from the other four (identically or similarly
sized) ATE1 isoforms by at most 5 kDa, and therefore size
differences alone would not suffice for identification of the iso-
forms in mouse cells. Isoform-specific antibodies would be
required to address these issues definitively. Work to produce
such antibodies is under way.
FIGURE3.ExpressionofATE1mRNAisoformsinmousetissues.RT-PCR-based
expression patterns of ATE11A7A, ATE11A7B, ATE11B7A, ATE11B7B, ATE11A7AB, and
ATE11B7ABmRNAs in the indicated tissues. See “Experimental Procedures” for the
namesof primers and their sequences. See also Fig. 2, A andB, and themain text.
Lane1, amplified cDNA (936bp) encodingN-terminal regionofATE11B7A. Lane2,
amplified cDNA (936bp) encodingN-terminal regionofATE11B7B. In adoubletof
barely resolvedbands fromthe testis-derived sample, the larger cDNA (1,065bp)
encodedATE11B7AB.Lane3,amplifiedcDNA(915bp)encodingN-terminal region
of ATE11A7A. Lane 4, amplified cDNA (915 bp) encoding N-terminal region of
ATE11A7B. In a doublet of bands fromeither the testis-derived ormuscle-derived
samples, the larger cDNAs (1,044 bp) encodedATE11A7AB. The doublets are indi-
cated by asterisks on the right.
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Our previous study (34) had shown that, in contrast to highly
similar ATE1 exon/intron patterns in the mouse and human
genomes, including the presence of alternative exons 7A and
7B, both the Drosophila melanogaster (arthropod) and Arabi-
dopsis thaliana (plant)ATE1 genes lacked the alternative inter-
nal exon 7A/7B arrangement. Drosophila contains just one but
still separate type 7 exon, whereasArabidopsis contains a type 7
exon as a part of a larger exon, the result of a fusion of several
exons that are separate in vertebrates. Examination of the
sequencedDrosophila andArabidopsis genomes confirmed the
earlier conclusions and indicated that these nonvertebrate
eukaryotes also lacked the mammalian ATE1 pattern of alter-
native first exons 1A/1B. Drosophila and Arabidopsis contain
only one such exon, and pufferfish (Takifugu rubripes), a verte-
brate, apparently has a single first exon too (data not shown), in
contrast to mammals and birds (Fig. 2, A–C).
To characterize ATE1 isoforms as enzymes and components
of the N-end rule pathway, we asked whether each of them
could confer metabolic instability, in ate1 S. cerevisiae (lack-
ing its own R-transferase), on Asp-gal, produced by the Ub
fusion technique (65) from Ub-Asp-gal and bearing N-termi-
nal Asp, a secondary destabilizing residue (Fig. 1A and Intro-
duction). Previous work (28, 34, 40, 63, 66) has shown that in
yeast the steady-state level of an X-gal reporter is a sensitive
measure of its metabolic stability. SGY3 S. cerevisiae (ate1)
was cotransformed with a low copy plasmid expressing an iso-
form of mouse ATE1 from the PGALS promoter and a high copy
plasmid expressing Asp-gal (Ub-Asp-gal) from the PGAL1
promoter. Controls included either vector alone or an other-
wise identical plasmid expressing S. cerevisiaeATE1. The levels
of X-gal proteins were determined by measuring the enzy-
matic activity ofgal in cell extracts. Using this assay (28, 34, 40,
63, 66), we found that, as expected, the previously characterized
isoforms ATE11B7A and ATE11B7B (34) conferred metabolic
instability on Asp-gal, with ATE11B7B being less active than
ATE11B7A (Fig. 4B), in agreementwith both the earlier evidence
(34) and a separate and direct arginylation test (see below). Fur-
thermore, ATE11A7AB and ATE11B7AB, the fifth and sixth iso-
forms (Fig. 2B) that contained both exons 7A and 7B, were
much less active than the other four isoforms (Fig. 4B). Control
immunoblotting tests (data not shown), using antibody to
mouse ATE1 (26), confirmed that at least the ATE11A7A,
ATE11B7A, and ATE11B7B isoforms (Fig. 2B) were expressed at
similar levels (less than 2-fold differences) in transfected ate1
ubr1 S. cerevisiae that yielded the results in Fig. 4B. Finally,
ATE11B(7AB) and ATE11B(7AB), two artificial (engineered)
deletion derivatives of the active R-transferases ATE11B7A and
ATE11B7B that lacked both of the internal exons 7A and 7B,
yielded the levels of Asp-gal that were indistinguishable from
those in ate1 yeast that lacked arginylation, strongly suggest-
ing an essential requirement for the (alternative) internal exons
7A or 7B (Fig. 4B).
In a different approach to some of these questions, we
employed an enzymatically direct in vitro test (as distinguished
from the degradation-coupled in vivo assay (Fig. 4B)). The test
used [3H]Arg, purified ATE1 isoforms, and -lactalbumin as a
reporter bearing N-terminal Glu, one of three secondary desta-
bilizing residues (Fig. 1A). In this previously described assay
(26, 36, 47), identical amounts of purified mouse ATE11A7A,
ATE11B7A, and ATE11B7B were incubated with -lactalbumin,
[3H]Arg, and an extract from ATE1/mouse EF cells (which
lacked R-transferases), followed by detection of the arginylated
reporter by SDS-PAGE and fluorography. ATE11A7A and
ATE11B7Awere highly active as R-transferases in this assay (Fig.
4A). In contrast, the activity of ATE11B7B was negligible at the
same level of the assay’s sensitivity (Fig. 4A) but was detectable
(albeit weakly) in a different [3H]Arg-based arginylation assay,
withATE1/ embryo extracts (Fig. 6A), in agreementwith the
FIGURE 4. Arginylation activity of mouse R-transferase isoforms. A, puri-
fied ATE11A7A can arginylate N-terminal Glu of a reporter protein. Lane 1,
extract from ATE1/ EF cells (0.25 mg of total protein) was incubated with
[3H]Arg under the conditions of arginylation assay (see “Experimental Proce-
dures”) but without added R-transferase, followed by SDS-PAGE and fluorog-
raphy. Lane 2, same but with ATE1/ extract. Lanes 3–5, same but with the
added (purified) ATE11B7A, ATE11B7B, andATE11A7A, respectively, at 1g each.
Lane6, sameas lane2butwith-lactalbumin (bearingN-terminalGlu). Lane7,
samebutwithATE1/ extract. Lanes 8–10, same as lanes 3–5,butwith-lac-
talbumin (the electrophoretic position of its arginylated derivative is indi-
cated by asterisk). Note the absence of activity of ATE11B7B at the level of
sensitivity of this assay (see themain text). B, the six isoforms of R-transferase
can metabolically destabilize, with different efficiencies, an otherwise long
lived Asp-gal reporter protein in ate1 S. cerevisiae (see “Experimental Pro-
cedures”). Values are the means  S.D., from three independent measure-
ments. The specific isoforms, as well as two deletion derivatives of ATE1, are
indicatedbelow thediagram.C, determination, through Edmandegradation,
of the N-terminal sequence of isolated Asp-gal reporter that had been
expressed in ate1 ubr1 S. cerevisiae either without or together with
ATE11A7A.
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weaker but detectable activity of ATE11B7B in the yeast-based
reporter-degradation assay (Fig. 4B).
The alternative splicing of mouse ATE1 pre-mRNA(s)
involves two pairs of the alternative and sequelogous (48)
exons, 1A/1B and 7A/7B (34) (Fig. 2C). Interestingly, the alter-
native exons 7A and 7B (Fig. 2A) (34) contain 5- and 3-splice
junction consensus sequences that are characteristic of introns
rather than exons (data not shown), suggesting the origins of
these alternative exons, over evolutionary time, from introns,
through a set of processes called “exonization” (67). Are the two
pairs of alternative exons in the ATE1 genes of mammals and
birds (Fig. 2C) a relatively recent feature, acquired during the
evolution of vertebrates, or does the alternative-exon organiza-
tion of ATE1 predate the divergence of animals and plants,
having been lost in most lineages but retained in some (not all)
extant vertebrate species? One difficulty in addressing this
issue definitively is that positive and negative selection pres-
sures are not the only evolutionary forces at work in such
settings, where random drift, through almost neutral muta-
tions, contributes significantly as well, especially in orga-
nismal lineages with relatively low population sizes such as
vertebrates (68). The evolutionary understanding of ATE1
would be advanced by the discovery of specific functions of
R-transferase isoforms (Fig. 2B).
While our findings about the isoforms of mouse ATE1 were
being prepared for publication, Rai and Kashina (61) published
a paper that described the identification of two of these iso-
forms, which they termed ATE1–3 and ATE1–4. These iso-
forms are identical to ATE11A7A andATE11A7B, respectively, of
the present work (Fig. 2B). Two additional new isoforms
described in the present work, ATE11A7AB and ATE11B7AB
(Figs. 2B, 3, and 4), bring the current number ofmouse R-trans-
ferase isoforms to six. In addition to describing two ATE1 iso-
forms, Rai and Kashina (61) presented evidence for two specific
properties of ATE1 R-transferases. First, they concluded that
the two new R-transferase isoforms (ATE11A7A and ATE11A7B
in the current terminology; see Fig. 2B) could not arginylate
substrates bearing N-terminal Asp or Glu (61), in contrast to
the previously characterized isoformsATE11B7A andATE11B7B
(34). Second, they concluded, on the basis of circumstantial
evidence (cycloheximide-based pulse-chases with mouse
ATE1/ EF cells and the RGS4 protein reporter), that all four
R-transferase isoforms could arginylateunmodifiedN-terminal
Cys (61).
Our data do not support the above conclusions. Specifically,
both ATE11A7A and ATE11A7B (which were described by Rai
and Kashina (61) as inactive with N-terminal Asp and Glu) are
actually active with these residues, as demonstrated by three
different tests (Fig. 4,A–C). At least one of these tests, the yeast-
based X-gal activity assay (Fig. 4B), is identical to the assay
used by Rai and Kashina (61). As mentioned above, the control
immunoblotting tests (data not shown), using antibody to
mouse ATE1 (26), confirmed that ATE11A7A, ATE11B7A, and
ATE11B7B (Fig. 2B) were expressed at similar levels (less than
2-fold differences) in the transfected ate1 ubr1 S. cerevisiae.
We further verified these results by employing a second assay,
also used by the above authors (61), namely the N-terminal
sequencing of X-gal reporters. Asp-gal was expressed in
ate1 ubr1 S. cerevisiae (deletion of UBR1 precluded degra-
dation of arginylated Asp-gal) in the presence of (coex-
pressed) ATE11A7A. The resulting gal reporter was isolated,
purified, and sequenced by Edman degradation, as described
previously (26, 34). More than 90% of Asp-gal isolated from
ate1 ubr1 S. cerevisiae that coexpressed ATE11A7A was
found to be the arginylated Arg-Asp-gal (Fig. 4C), thus
directly confirming the conclusion from yeast-based X-gal
activity assays (Fig. 4B).
We do not know the reason for this direct discrepancy
between our experimental data (Fig. 4) and the data by Rai and
Kashina (61). Because no controls verifying that R-transferases
were actually expressed (as proteins) in the tester yeast strain
were mentioned in the cited study, one possibility (which, if
correct, would account for the above discrepancy) is that the
apparent lack of activity reported by the authors (61) stemmed
from negligible expression levels of the tested mouse ATE1s in
S. cerevisiae.
Rai and Kashina (61) also observed that mouse RGS4, an
N-end rule substrate that bears N-terminal Cys and is targeted
for degradation by the arginylation branch of the N-end rule
pathway (26, 35, 37) (see Introduction), was short lived in argi-
nylation lacking ATE1/ mouse EF cells that had been tran-
siently transfected with cDNAs encoding any one of the four
tested mouse ATE1s. From this (inherently indirect) evidence,
they concluded that mouse R-transferases, in contrast to S. cer-
evisiaeR-transferase, couldmediate the arginylation of unmod-
ifiedN-terminal Cys (61).However, our earlier study has shown
that RGS4 isolated frommouse cells that had been treated with
proteasome inhibitor (to prevent the destruction of arginylated
RGS4) was not only arginylated but also contained a modified
Cys residue at position 2, specifically Cys sulfonate (36). This
result was followed by our recent study that demonstrated,
using direct enzymatic tests with purified R-transferases, that
the activity of either mouse or S. cerevisiae ATE1s toward
unmodified N-terminal Cys was negligible and that NO-medi-
ated oxidation of N-terminal Cys was required for its (subse-
quent) arginylation, both in vitro and in vivo (26).
The ATE1 Promoter—Analyses, using PromoterInspector
(Genomatix) of the20-kb segment upstream ofmouseATE1,
pinpointed an 700-bp region immediately upstream of exon
1B that appeared to comprise a part ofATE1 promoter (PATE1).
To identify putative cis-acting sequences of PATE1, we tested
fragments of genomic DNA that encompassed the above
region, using a double-luciferase reporter system and transient
cotransfections of NIH-3T3 cells. The measured levels of the
firefly luciferase reporter, whose expression was driven by var-
ious DNA regions upstream of exon 1B (Fig. 2D), were com-
pared with the levels of firefly luciferase driven by the control
(PSV40) promoter (Fig. 5, B, D and E). Whereas constructs con-
taining the segment from1,603 to543 bp (pCB30; region 3)
or the segment from 2,083 to 543 bp (pCB40; region 3–4)
upstream of exon 1Bwere unable to drive luciferase expression,
the constructs that contained the segment2,083 to223 bp
(pCB41; region 2–4) or the segment from 1,603 to 223 bp
(pCB43; region 2–3) yielded significant but modest levels of
luciferase expression, 50 and 30% of the control (PSV40-con-
ferred) levels, respectively (Fig. 5, B, D, and E). In contrast, the
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segment from2,083 to32 bp (pCB42; region 1–4) produced
3.5-fold higher levels of luciferase than the control (PSV40)
promoter, with a further increase to4.5-fold for regions 1–3,
from1,603 to32 bp (pCB44) (Fig. 5, B, D, and E). The latter
result suggested that the region from 2,083 to 1,603 bp
(region 4) contained motifs that repressed transcription. In
summary, the addition of a 192-bp fragment, located between
223 and32 bp (region 1), to the2,083/223-bp segment
(region 2–4) increased luciferase expression by6-fold (com-
pare pCB42 and pCB41) and by14-fold in the absence of the
repressive region 4 (compare pCB44 and pCB43) (Fig. 5, B, D,
and E).
The 192-bp region-1 segment could drive luciferase expres-
sion by itself, at the level comparable with that of the control
(PSV40) promoter. This region, directly upstream of exon 1B,
sufficed as a promoter under these conditions (compare
pCB59F to pSV40; Fig. 5, B and E). Similarly to the sequences of
ATE1 exons, the sequence of this promoter region is highly
conserved among the human, mouse, rat, and other examined
vertebrate genomes, whereas DNA sequences outside this
region are much less conserved, as determined using percent
identity plot. Interestingly, this promoter motif is located
between the alternative exons 1A and 1B, indicating that addi-
tional promoter elements must exist upstream of (alternative)
exon 1A that drive the expression of ATE1mRNAs containing
exon 1A (Fig. 2D and Fig. 5, A and B).
Promoter-relevant regions predicted by PromoterInspector
encompassed, in addition to the region 1, about 500 bp of the
adjacent upstream sequence as well. The addition of the region
2 (543/223 bp) yielded an 4-fold increase in luciferase
levels over that of the region 1 alone (compare pCB59F to
pCB107) (Fig. 5, B, D and E). Furthermore, although the much
larger region 1–3 (1603/32 bp) (pCB44) conferred lucifer-
ase levels 4.5-fold higher than the control (PSV40) promoter,
the otherwise identical segment that lacked the region from
543 to 223 bp (pCB60F; region 1 and 3) yielded luciferase
FIGURE 5.Detection and analysis of a bidirectional promoter element in themouse ATE1 gene. A, diagram of (G C) content of genomic DNA (30 kb)
encompassing the 5-region of ATE1 reveals a CpG island between the alternative exons 1A and 1B. Positions of the first nine ATE1 exons (1A through 7B) are
shown below the (G C) pattern. The first nucleotide of ATE1 exon 1B is denoted as1. B, the 192-bp segment immediately upstream of ATE1 exon 1B can
function as bidirectional promoter. The diagram shows segments of genomic DNA upstream of ATE1 exon 1B that were tested for their ability to direct the
expression of luciferase gene in transfectedmouse cells. C, Northern analysis of expression of a previously uncharacterizedmouse gene adjacent to ATE1 and
transcribed in the opposite direction6 (see Fig. 2D and “Experimental Procedures”). The arrow indicates themain RNA species, with strongest expression in the
testis. Actin mRNA probe was used to verify the uniformity of total RNA inputs. D and E, expression of luciferase, measured using a dual luciferase assay with
extracts from NIH-3T3 cells transfected with pGL3-based plasmids that contained upstream DNA segments indicated in B. Luciferase levels are plotted in
relative light units, normalized against the sample with PSV40 plasmid, arbitrarily assigned 1 light unit. Values are the means S.D., from three independent
measurements.
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levels that were only 1.6 times higher than those by PSV40 or
by the 192-bp fragment alone (Fig. 5, B, D, and E). We con-
cluded that positive promoter elements of PATE1 encompassed
both the critical 192-bp region 1 (223/32 bp) and the adja-
cent upstream region 2 (543/223 bp) (Fig. 2D and Fig. 5, A
and B).
The observed spatiotemporal complexity of ATE1 expres-
sion in both embryonic (36) and adult tissues,5 as well as the
presence of (alternative) exon 1A upstream of the currently
defined promoter region, imply that the cis-acting elements
identified so far (Fig. 2D and Fig. 5B) are but a part of the mul-
tisite, modular PATE1 promoter, whose complete span remains
to be determined. Our attempts, based on the dual-luciferase
assay, to identify transcription-enhancing promoter elements
upstream of exon 1A were unsuccessful thus far (pCB30 and
pCB40; Fig. 5, B, D, and E). In addition, analyses of the10-kb
region upstreamof exon 1Aby PromoterInspector did not yield
candidate sequences either significantly or immediately
upstream of exon 1A. Further work to identify such sequences
is under way.
Bidirectionality and CpG Island of the ATE1 Promoter—The
mean G  C content of 30 kb of the mouse genomic DNA,
from10 kb upstream to20 kb downstreamofATE1 exon 1B
was 40%. In contrast, an 800-bp region containing both
exons 1A and 1B, from680 bp upstream of exon 1B to120
bp downstreamof exon 1B, had themeanGC content of 75%
(Fig. 5A and supplemental Fig. S2). Closer inspection identified
85 CpG dinucleotide repeats in this region (Figs. 5A and sup-
plemental Fig. S2). About half of these CpGs resided in a seg-
ment directly upstream of the ATE1 exon 1B that includes the
highly conserved 192-bp region 1, shown to function as the core
promoter element between the alternative exons 1A and 1B
(Fig. 2D and Fig. 5A). High density of CpG repeats is a charac-
teristic feature of previously identified bidirectional promoters
in metazoan genomes (69–77). Although the number of actu-
ally characterized bidirectional promoters remains low, current
estimates suggest that more than 10% of genes in a mammalian
genome may be present as closely apposed head-to-head pairs
transcribed from bidirectional promoters (75–77).
The 192-bp region-1 DNA segment was indeed found to
drive the expression of a luciferase reporter in both orientations
(Fig. 5, B, D, and E). Moreover, linking the region 3 (1,603/
543 bp) to the oppositely oriented region 1 enhanced the
expression of luciferase, similarly to the effect of region 3
(1,603/543 bp) on the naturally oriented region 1 segment
(compare pCB59R to pCB60R and pCB59F to pCB60F; Fig. 5, B
and E). We also made constructs, pCB107 and pCB108, that
contained the entire region 1–2 (543/32 bp) in either ori-
entation (Fig. 5B). Whereas pCB107 conferred high levels of
luciferase expression, the same fragment in the opposite orien-
tation was essentially inactive, indicating that the property of
bidirectionality is confinedmostly to the smaller (192 bp) CpG-
rich region 1 promoter element embedded in a larger CpG
island (Figs. 2D, Fig. 5, A, B, and D, and supplemental Fig. S2).
Thus, the region 1, an evolutionarily conserved, CpG-rich
genomic DNA fragment at the 223/32 position relative to
the start codon of the mouse ATE1 exon 1B can function as a
bidirectional promoter in transient transfection assays with
luciferase reporter.
To determine whether the CpG-rich region-1 bidirectional
element functioned similarly in the context of genomic ATE1
locus, we carried out Northern hybridization of poly(A) RNA
from adult mouse tissues, using a probe derived from genomic
DNA upstream of the bidirectional promoter region. To detect
transcripts that were distinct from those encoding ATE1 iso-
forms (e.g. those containing exon 1A), the probe was designed
so that it did not overlap with either ATE1 exon 1A or its
(expected) 5-untranslated region, the latter suggested by infor-
mation in the GenBankTM EST entries AW105867 and
CJ144976 (data not shown). A low level 2-kb transcript was
detected in the heart, brain, spleen, lung, liver, and kidney but
not in skeletal muscle (Fig. 5C). Although we still do not know
the location of promoter elements that yield ATE1 transcripts
containing exon 1A (see above), the ongoing analyses6 of a new
gene that is transcribed in the direction opposite to that of
ATE1 made the assignment of transcripts described below
definitive (data not shown). In particular (to cite just the evi-
dence relevant to the specificity of detection of oppositely ori-
ented transcripts by Northern), the exon 1A-containing ATE1
transcripts were clearly expressed in skeletal muscle, as
detected by RT-PCR (Fig. 3, lanes 3 and 4). In contrast, the
Northern probe used to detect transcripts of the oppositely ori-
ented gene did not detect any such transcripts in the muscle, in
contrast to other tissues (Fig. 5C).
Interestingly, the 2-kb transcript was highly expressed in
the testis, together with additional probe-hybridizing tran-
scripts, of4.5,2.3, and	1.35 kb (Fig. 5C). This and related
results identified a set of novel transcripts in mouse cells that
are encoded by a previously uncharacterized gene in the vicinity
of the 192-bp bidirectional promoter element but in the oppo-
site orientation to ATE1, and partially overlapping with it.
Investigations of this gene and its products are underway.6
Substrate Preferences of ATE11A7AVersus ATE11B7A—In part
to attempt in vitro identification of new physiological sub-
strates of the N-end rule pathway, and also because we wished
to determine whether different R-transferase isoforms had
preferences for specific substrates, we employed the [3H]Arg-
based arginylation assay, using extracts from 12.5-day-old
(E12.5) mouse embryos (26, 36). To preclude the in vivo argi-
nylation and to make certain that only a specific (added) iso-
form of R-transferase was responsible for arginylation in this in
vitro assay, the extracts were prepared from previously
described (36) ATE1/ embryos, which lacked arginylation.
Specific epitope-tagged R-transferase isoforms (ATE11A7A,
ATE11B7A, and ATE11B7B; see Fig. 2B) were expressed in insect
cells using recombinant baculoviruses andwere purified to near
homogeneity. The mouse embryo extracts used, termed S105,
were supernatants after centrifugation of total extracts at
105,000 g, a step that removes the bulk of ribosomes. Besides
an S105 extract (either/ orATE1/), the reactionmixture
5 J. Sheng, R. Solomatina, K.-J. Shin, R.-G. Hu, and A. Varshavsky, unpublished
data. 6 C. Brower, L. Veiga, R. Jones, and A. Varshavsky, unpublished data.
Arginyltransferase
32568 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 281•NUMBER 43•OCTOBER 27, 2006
 at CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y on Novem
ber 10, 2006 
w
w
w
.jbc.org
D
ow
nloaded from
 
contained the following: [3H]Arg; a purified mouse R-transfer-
ase (ATE11A7A, ATE11B7A or ATE11B7B); puromycin to inhibit
possible (residual) translation in S105; ATP regeneration sys-
tem; a mixture of E. coli tRNAs and aminoacyl-tRNA syntheta-
ses to produce Arg-tRNA; the Arg-Ala dipeptide to inhibit pos-
sible ubiquitylation of arginylated proteins in the extract;
MG132, a proteasome inhibitor, to reduce possible degradation
of arginylated proteins; and a set of standard protease inhibi-
tors. The reactions were carried out at 37 °C for 1 h, followed by
removal of unincorporated [3H]Arg and the processing of sam-
ples for electrophoresis and fluorography.
This approach stemmed from our earlier detection, using
specific antibodies, of greatly increased in vivo levels of RGS4,
RGS5, and RGS16 in ATE1/ embryos (26). That in vivo-
based finding, in conjunction with additional evidence, indi-
cated that these regulatory proteins (see Introduction) were
physiological substrates of the arginylation branch of theN-end
rule pathway (26). This result also implied that comparing the
levels of in vitro-arginylated proteins between otherwise iden-
tical extracts from wild-type (/) and ATE1/ embryos
would help distinguish, under such conditions, between (puta-
tive) physiological substrates of R-transferase and artifactually
arginylated proteins, because the former, but not the latter,
would be expected to be present at higher levels in ATE1/
extracts, having been spared the in vivo arginylation and degra-
dation. A problem that makes this ATE1/-based approach
particularly helpful stems from the fact that compartments
such as the ER andGolgi contain a number of proteins that bear
destabilizing (including arginylatable) N-terminal residues.
These proteins had been cleaved by signal peptidase during
their translocation into the ER, and the cleavage specificity of
this peptidase often yields a destabilizing residue at the N ter-
minus of a translocated, compartmentalized protein (23). Even
if detergents are absent during preparation of extracts, a com-
partmentalized protein may partially “leak” (from membrane
vesicles to be removed by centrifugation) into the cytosolic
fraction and become arginylated in an in vitro assay. An
ATE1/ extract and a / extract would be expected not to
differ significantly by the levels of “leaked” proteins, in contrast
to the levels of proteins that are arginylated and degraded by the
N-end rule pathway in/ cells. (Note that some ER or Golgi
proteins can be present, in vivo, in the cytosol and/or the
nucleus as well. Thus, not all ER or Golgi proteins, if they are
found to be arginylated in vitro, are necessarily artifacts; see
below.)
In the absence of added R-transferases, no incorporation
of [3H]Arg could be detected with ATE1/ embryo
extracts, confirming the absence of both R-transferases and
(residual) translation in this setting (Fig. 6A, lane 1). The
same test with / embryo extracts showed low levels of
[3H]Arg incorporation, mediated by endogenous R-trans-
ferases (Fig. 6A, lane 2). When a purified R-transferase, such
as ATE11B7A, was added to the above assay, the resulting
patterns of [3H]Arg incorporation were different between
/ and ATE1/ extracts, as could be shown by two-di-
mensional electrophoresis (Fig. 6, B–D). This result was
obtained with ATE11A7A and ATE11B7A R-transferases (Fig. 6
and data not shown). Remarkably, this approach revealed that
purified ATE11A7A or ATE11B7A, when added at identical levels
to identical samples of the E12.5ATE1/ embryo extract, pro-
duced overlapping but significantly different patterns of argi-
nylation, suggesting that these two R-transferases, which differ
exclusively by their (sequelogous) N-terminal exons 1A and 1B
(Fig. 2, B and C), have distinct preferences for specific protein
substrates. Both of these R-transferases had comparable activ-
ities in the yeast-based in vivo degradation assay with an argi-
nylation reporter such as Asp-gal (Fig. 4B). However, the
yeast-based assay, in which R-transferases were overexpressed,
would havemissed significant but not all-or-none differences in
the levels of activity of specific R-transferase isoforms. Some of
the differences between the ATE11B7A-specific and ATE11A7A-
specific arginylation patterns are indicated by circles in Fig. 6D.
Thus, specific isoforms of R-transferase may have distinct
functions. For example, although all of the isoforms are capable
of arginylating N-terminal Asp, Glu, and (oxidized) Cys, the
FIGURE 6.GRP78 (BiP) andprotein-disulfide isomerase as putativeN-end
rule substrates. A, arginylation assay, with [3H]Arg, mouse embryo extracts,
and one-dimensional SDS-PAGE, followed by fluorography. Lane 1, with
extract from E12.5 ATE1/ embryos, lacking R-transferases. Lane 2, same but
with ATE1/ embryos. Lane 3, same as lane 1 but with purified ATE11B7A
added to ATE1/ extract. Lane 4, same but with purified ATE11B7B. Lane 5,
same but with purified ATE11A7A. (Note a much lower activity of ATE11B7B, in
agreement with the results of assays in Fig. 3, A and B.) B, arginylation assay,
with [3H]Arg, ATE1/ embryo extract (with endogenous R-transferases) and
two-dimensional electrophoretic analysis, followed by fluorography. C, same
but with E12.5 ATE1/ embryos and ATE11B7A. D, same but with ATE11A7A.
Molecular masses of marker proteins (not shown) are indicated. Three circled
protein spots in D indicate, from the top circle down, an unknown protein,
GRP78, and PDI, respectively. The latter proteins were identified by mass
spectrometry (see the main text). Other also readily observable differences
between two-dimensional patternswithATE1/embryos (B) versus ATE1/
embryos (C) and between ATE11B7A (C) versus ATE11A7A (D) remain to be
addressed and are unmarked.
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relative rates of arginylation, e.g. of Asp versus Glu, may differ
among the isoforms. Yet another (nonalternative) possibility is
that specific sequence and conformational features down-
streamof (arginylatable)N-terminal residues of a substratemay
lead to physiologically relevant differences in the rate of sub-
strate’s arginylation by different isoforms of R-transferase. Our
previous work (34) and more recent mutagenesis studies7 indi-
cated that N-terminal regions of R-transferases are essential for
their activity and are likely to be a part of a substrate-binding
domain. Thus, the distinct but sequelogous exons 1A and 1B,
encoding N-terminal regions of ATE11A7A and ATE11B7A (Fig.
2, B and C), respectively, may confer physiologically relevant
substrate preferences on these isoforms of R-transferase. In
addition, different spatial locations of R-transferase isoforms in
a cell (little is known about this at present (34)) may further
modulate their intrinsic preferences for specific substrates.
There is extensive precedent for the notion that different splic-
ing-derived isoforms of an enzyme can have distinct locations
in a cell and thereby different functions (78–83).
Putative N-end Rule Substrates GRP78 and PDI—Some of
the spots of proteins thatwere arginylated byATE11A7A but not
by ATE11B7A in ATE1/ extracts (Fig. 6, C and D) were
excised and sequenced, using digestion with trypsin and
MS/MS mass spectrometry (see “Experimental Procedures”).
Two of these arginylated proteinswere found to beGRP78 (glu-
cose-regulated protein 78) and PDI, in agreement with their
apparent molecular masses and isoelectric points in two-di-
mensional electrophoretic patterns (Fig. 6D and data not
shown). Other proteins that were arginylated by ATE11A7A or
ATE11B7A in ATE1/ but not in ATE1/ embryo extracts
(Fig. 6 and data not shown) remain to be identified.Mammalian
GRP78, also referred to as BiP, is an abundant 70-kDa protein, a
member of the family of HSP70 stress proteins, and a major
chaperone in the lumen of ER, where the bulk of GRP78 resides
(84). Mammalian PDI (PDIA1) is a 55-kDa protein-disulfide
isomerase. It catalyzes disulfide bond formation, reduction, or
isomerization, is a member of the family of structurally related
PDI enzymes, functions also as a molecular chaperone, and
resides largely in the lumen of ER (85). As nascent proteins,
mammalian GRP78 and PDI bear N-terminal signal sequences
that are cleaved by signal peptidase upon their translocation
into the ER, yielding Glu and Asp, respectively, at the N termini
of translocated GRP78 and PDI. Both of these N-terminal res-
idues are Nds residues in the N-end rule (Fig. 1A) and would
therefore be expected to be arginylated by R-transferases, in
agreement with our in vitro results (Fig. 6D).
The [3H]Arg-labeled spots ofGRP78 andPDIwere present in
the extracts fromATE1/ embryos (containing an added spe-
cific R-transferase) but not in extracts from ATE1/ embryos
(containing a set of endogenous R-transferases) (Fig. 6, B–D).
This strongly suggested that the in vitro-arginylatedGRP78 and
PDI did not result from artifactual “leakage” of ER proteins into
the cytosolic fraction during preparation of these extracts, an
inference consistent with the earlier lines of evidence that both
PDI and GRP78 can also occur, in vivo, outside the ER (57–60).
Nevertheless, our evidence that the two proteins are physiolog-
ical substrates of R-transferase (implying their cytosolic and/or
nuclear localization), although strongly suggestive, is still indi-
rect, because it remains formally possible that subsets ofGRP78
and PDImight have leaked from the ER andwere arginylated by
endogenous R-transferases in the ATE1/ extract (but not in
the ATE1/ extract) before the addition of [3H]Arg, despite
the near 0 °C temperature during the processing of extracts
and despite a likely decrease of endogenousArg-tRNAunder in
vitro conditions, before the addition of aminoacyl-tRNA syn-
thetases and tRNA.
Yet another possibility is that the absence of arginylation in
ATE1/ embryos may increase the expression levels of ER-
localizedGRP78 and PDI, in comparison toATE1/ embryos.
Note, however, that even if GRP78 and PDI were, in fact,
induced in the absence of R-transferase, that effect alone would
not preclude the possibility that these proteins are bona fide in
vivo substrates of the N-end rule pathway. The “overexpres-
sion” interpretation was made unlikely by the data (not shown)
that indicated similar total levels of, respectively, GRP78 and
PDI in E12.5 ATE1/ embryos versus ATE1/ embryos, as
determined by immunoblotting with antibodies to GRP78 and
PDI. Although informative otherwise, such data cannot distin-
guish between the levels of GRP78 and PDI in the ER (their
major location) and the presumably much lower (and inde-
pendently changing) levels of GRP78 and PDI at their non-ER
locations in a cell (see below). This is an illustration of the dif-
ficulty in addressing, definitively, the biological meaning of the
above in vitro results (Fig. 6,B–D).We should alsomention that
the above identification of two spots of arginylated proteins in
Fig. 6 as GRP78 and PDI, although direct and robust as an
MS/MS-based evidence, is, strictly speaking, an interpretation
of data, because of the formal possibility that other (arginylat-
able) protein species comigrated with GRP78 or PDI in two-
dimensional electrophoretic fractionations. Although unlikely
for several reasons, this possibility is formally unexcluded. Hav-
ing identified GRP78 and PDI as putative arginylation sub-
strates, our further work in this area aims to bypass in vitro
approaches, by developing an in vivo-basedmethod to solve the
problemofwhichGRP78 andPDI are the first examples: how to
identify, in vivo, a subset of molecules of a given protein that
may undergo arginylation (or other modifications) in the
cytosol, for example, if the bulk of this protein resides in
another compartment such as the ER.
Remarkably, there is an independent and functionally rele-
vant evidence for the in vivo location of a fraction of both
GRP78 and PDI on the cytosolic side of the ER. Stockton et al.
(57) identified a protein complex, termed the translocon-resi-
dent protein-disulfide isomerase complex (TR-PDI), that
included both PDI and GRP78 and was present in the cytosol,
where it interacted with the cytosolic face of SEC61, the major
component of ER translocation channel. Specific aspects of the
TR-PDI complex remain to be clarified, including its function
in protein translocation, the paths that GRP78 and PDI take to
form this complex, and the metabolic fates of TR-PDI’s com-
ponents, including GRP78 and PDI (57). For example, in order
to form the TR-PDI complex, must these proteins be retro-
translocated from the ER into the cytosol, with their signal7 R.-G. Hu, H. Wang, and A. Varshavsky, unpublished data.
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sequences cleaved off earlier? Or does TR-PDI consist of pro-
teins that did not enter the ER, as yet, and therefore retained
their signal sequences, bearing the initial, stabilizing N-termi-
nal residues? One possibility is that the former route to TR-PDI
is the actually taken one, at least with GRP78 and PDI. If so,
these proteins bearing, respectively, Glu and Asp at the N ter-
mini (see above)may be arginylated and degraded by theN-end
rule pathway upon, for instance, dissociation of the TR-PDI, if
such is the dynamics ofTR-PDI in vivo. Thismodel is consistent
with in vitro properties of theTR-PDI complex (57).Oneway to
address these issues would be to determine whether the N ter-
mini of GRP78 and PDI in the TR-PDI complex are either
already arginylated or can be arginylated upon dissociation of
TR-PDI. One can also ask, using previously constructed mouse
ATE1/ cell lines (26, 36), whether TR-PDI-derived GRP78
and PDI in these cells (a subset of total GRP78 and PDI) become
short lived upon re-expression of R-transferase.
Another study, by Grune et al. (60), showed that transient
treatment of a rat liver cell line with H2O2 resulted in a degra-
dation-mediated decrease of PDI, one of two proteins identified
above as putative in vivo substrates of R-transferase. The oxi-
dation-induced in vivo degradation of PDI wasmediated by the
proteasome (60), and therefore must have taken place in the
cytosol and/or the nucleus. The N-terminal sequence of PDI
from these cells, determined by Edman sequencing, lacked the
(initially present) signal sequence, thus identifying the bulk of
sequenced PDI as either a luminal ER protein (the main loca-
tion of PDI) or a protein retrotranslocated from the ER. In the
N-terminally sequenced PDI, its (arginylatable) Asp-26 residue
was the second residue, and the identity of the first residue was
unclear (60). One possibility (not the only one) is that the first
residue was not the encoded Ser-25 but the post-translationally
conjugated Arg residue. If so, this (oxidatively damaged?) spe-
cies of PDI could be a specific subset of PDI in a cell, retrotrans-
located from the ER and arginylated byATE1-encodedR-trans-
ferases, thus becoming a target for the rest of the N-end rule
pathway and thereby possibly accounting for the findings of
Grune et al. (60). This currently speculativemodel can be tested
using approaches mentioned above in the context of GRP78.
Concluding Remarks—N-terminal arginylation, a protein
modification universal among eukaryotes and apparently con-
fined to them (47), is mediated by ATE1-encoded R-trans-
ferases and is a part of theN-end rule pathway, a Ub-dependent
proteolytic system (Fig. 1A). The functions of the arginylation
branch of the N-end rule pathway include the regulation of
cardiovascular development and homeostasis (36, 39), the reg-
ulation of signaling by NO and oxygen (26, 37) (this regulation
is likely to subserve, in particular, the pathway’s cardiovascular
functions), the regulation of apoptosis (51, 52), the regulation of
leaf senescence in plants (53), and the regulation of chromo-
some mechanics through the arginylation-dependent degrada-
tion of the separase-produced fragment of a subunit of mam-
malian cohesin3 (see Introduction for additional information
and references). Although it is possible that mouse ATE1 gives
rise to more than six splicing-derived mRNA isoforms
described above, including twonew isoforms (Fig. 2,B–D), both
our present work and preceding efforts to identify ATE1 iso-
forms (34, 36, 61) suggest that the current set may be the com-
plete one. We do not know, as yet, whether R-transferase iso-
forms have distinct functions. The current circumstantial
evidence suggests this possibility, given strong variations in
expression levels of specific ATE1mRNA isoforms in different
mouse tissues (34) (Fig. 3), and also the observed differential
activity of the ATE11A7A versus ATE11B7A isoforms toward
putative physiological substrates (Fig. 6).
Another set of new findings reported and discussed above
includes the discovery of bidirectionality of theATE1 promoter
(PATE1), specifically the ability of an 200-bp DNA segment
(region 1) immediately upstream of the start codon of exon 1B
(which encodes one of two alternative N termini of R-transfer-
ase; Fig. 2, B–D) to function as a promoter in both orientations.
This short CpG-rich segment of PATE1 is bidirectional not only
inmodel (transfection-based) settings but also inmouse tissues
in vivo, where it mediates, at least in part, the transcription of
bothATE1 and an oppositely oriented, previously uncharacter-
ized gene, which is expressed in several mouse tissues (Fig. 2D
and Fig. 5D). Our findings about this (second) gene will be
described elsewhere.6 Although bidirectional promoters
(whose features include the presence of CpG islands) appear to
mediate the expression ofmore than 10%of genes in amammal,
relatively few examples of transcriptional bidirectionality have
been characterized thus far in mammals, and even fewer bidi-
rectional promoters were analyzed in detail (69–77). Our find-
ing that PATE1 is bidirectional adds an unexpected dimension to
the understanding of this promoter, whose spatiotemporal and
cell type-specific regulation is known to be complex5 (36).
Although the 200-bp bidirectional promoter element is
upstream of the start codon of the ATE1 exon 1B, it is down-
stream of the alternativeATE1 exon 1A (Fig. 1F). This arrange-
ment is consistent with interesting possibilities, such as regula-
tion of ATE1 and the (oppositely oriented) adjacent gene
through transcriptional interference and/or, for example, the
formation, through bidirectional transcription in this region, of
double-stranded RNA molecules, a hallmark of RNA interfer-
ence (86). One of many remaining questions about PATE1 is the
location of its element(s) that mediates the formation of
mRNAs encoding ATE11A7A and the other two exon 1A-con-
taining ATE1 isoforms (Fig. 2, B–D).
Yet another set of new results is the identification of two
putative physiological substrates of mouse R-transferases that
are distinct from the previously known (and definitively identi-
fied) RGS4, RGS5, and RGS16 (26, 37) (see Introduction). The
above RGS proteins are conditionally short lived proteins that
are targeted for the arginylation and degradation via the NO-
dependent activation of their Cys-based N-degrons. Given the
tripartite structure of N-degrons, it is possible that some phys-
iological substrates of R-transferase would be found to lack a
complete N-degron, i.e. that their arginylation would not be
followed by their degradation.
The two substrates of R-transferase described in the present
work are GRP78 (BiP), an ER-localized chaperone, and PDI,
another ER-localized enzyme. Both of these proteins are still
putative N-end rule substrates, given their in vitro (but geneti-
cally based) identification (Fig. 6 and discussion above), and the
localization of the bulk of these proteins in the ER, a compart-
ment that lacks the N-end rule pathway (23). However, several
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lines of evidence, described above, suggest that bothGRP78 and
PDI can be present in other cellular compartments as well,
including the cytosol and the nucleus (57–60), where these pro-
teins may be N-end rule substrates. Whether this is actually so
in vivo and the functions of degradation of GRP78 and PDI by
the N-end rule pathway remain to be determined.
The findings of the present work aboutmouseATE1, its bidi-
rectional promoter, alternative splicing, the resulting R-trans-
ferase isoforms, and their putative physiological substrates
raised a number of new questions. Studies to address them are
under way.
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